$QNCX News

Last published 2w ago

2w agoQNCXIRulya Therapeutics (IRLA) Fireside Chat (FKA Orphai) - IRULYA THERAPEUTICS INCEarnings Call TranscriptsAll right. Hello, everyone. I'm Albert Lo, Senior Biotech Analyst, and thank you for joining our Craig Hallam Biotec Catalyst Conference. And I want to welcome our live viewers to submit their questions here on the webca
1mo agoQNCXQuince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for
2mo agoQNCXQuince Therapeutics to Participate in September 2026 Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for
2mo agoQNCXQuince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate UpdateGlobeNewswireCompleted acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD
4mo agoQNCXQuince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory BoardGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for
5mo agoQNCXUPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDGlobeNewswireData from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD
5mo agoQNCXQuince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary PipelineGlobeNewswireAcquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome
5mo agoQNCXQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDGlobeNewswireData from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD
7mo agoQNCXQuince Therapeutics Settles Approximately $16.4 Million of DebtBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX) today announced the successful settlement of the company's outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. This marks
9mo agoQNCXQuince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic AlternativesBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic alternatives aimed at
9mo agoQNCXQuince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-TelangiectasiaBusiness WirePrimary and key secondary endpoint did not achieve statistical significance eDSP was generally well tolerated with no clinically meaningful safety concerns identified Company to cease clinical development of eDSP;
9mo agoQNCXQuince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual MeetingBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of
11mo agoQNCXQuince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-TelangiectasiaBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the last patient has
11mo agoQNCXQuince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel DisordersBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the publication of a summary of
11mo agoQNCXQuince Therapeutics to Participate at Investor Events in December 2025Business WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that senior management will
12mo agoQNCXQuince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial ResultsBusiness WirePivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026 Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage
1y agoQNCXQuince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaBusiness WireNo safety concerns identified by independent data and safety monitoring board, which recommends continuation of study without any modifications Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology
1y agoQNCXQuince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual MeetingBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of
1y agoQNCXQuince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling StudyBusiness WireQuince Therapeutics, Inc.
1y agoQNCXQuince Therapeutics to Host Virtual Investor Day on October 2, 2025Business WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it will host a virtual
1y agoQNCXQuince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's
1y agoOPCH QNCXQuince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsBusiness WireMarks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing
1y agoOPCH QNCXQuince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSPBusiness WireProvides access to broad-reaching nationwide network of specialty pharmacy and ambulatory infusion suites across the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to
1y agoQNCXQuince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the company has completed
1y agoQNCXQuince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory BoardBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan
1y agoQNCXQuince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research ConferenceBusiness WirePhase 3 NEAT enrollment momentum continues with 99 total participants enrolled to date Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own
1y agoQNCXQuince Therapeutics Announces Closing of Up to $22 Million Private Placement of SecuritiesBusiness WireFinancing priced at a premium; led by healthcare-focused institutional investor Nantahala Capital with participation from existing Quince stockholders including ADAR1 Capital Management, along with members of Quince's
1y agoQNCXQuince Therapeutics Announces Pricing of Up to $22 Million Private Placement of SecuritiesBusiness WireFinancing to provide $11.5 million in upfront proceeds with up to an additional $10.4 million of proceeds assuming exercise in full of the warrants Financing priced at a premium to last close Quince Therapeutics,
1y agoQNCXQuince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT
1y agoQNCXQuince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsBusiness WirePlan to potentially conclude enrollment early for Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) to align topline results with existing cash runway Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage
1y agoQNCXQuince Therapeutics to Present at Citizens Life Sciences ConferenceBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's
1y agoQNCXQuince Therapeutics to Present at Jones Healthcare and Technology Innovation ConferenceBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's
1y agoQNCXQuince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial ResultsBusiness WirePhase 3 NEAT clinical trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomization Existing cash position of $40.8 million expected to provide operating runway
1y agoQNCXQuince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-TelangiectasiaBusiness WirePhase 3 NEAT clinical trial nearing 50% enrollment; company reiterates expectation of enrollment completion in second quarter of 2025 and topline results in fourth quarter of 2025 Quince Therapeutics, Inc.
1y agoQNCXQuince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's
1y agoQNCXQuince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-TelangiectasiaBusiness WireAllowance to extend into 2036 patent claims related to method of treating patients with A-T using the company's proprietary EryDex process Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company
1y agoQNCXQuince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-TelangiectasiaBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it will host an investor
1y agoQNCXQuince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-TelangiectasiaBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the online publication of safety data
1y agoQNCXQuince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory BoardBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William
1y agoQNCXQuince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsBusiness WirePhase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company
1y agoQNCXQuince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia ResearchBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the presentation of two posters
2y agoQNCXQuince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual MeetingBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation at the
2y agoQNCXQuince Therapeutics to Participate at Upcoming Investor ConferencesBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that management will present at
2y agoQNCXQuince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's
2y agoQNCXQuince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)Business WireFindings from largest completed study in A-T demonstrated favorable safety profile Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age range that typically
2y agoQNCXQuince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial ResultsBusiness WireStrong cash position expected to provide sufficient operating runway into 2026; Phase 3 topline results expected in the fourth quarter of 2025 Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology
2y agoQNCXQuince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-TelangiectasiaBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today
2y agoQNCXQuince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex SystemBusiness WireFast Track designation underscores the high unmet medical need, with currently no approved therapeutic treatments for the rare pediatric disease Ataxia-Telangiectasia Quince Therapeutics, Inc. (NASDAQ:QNCX), a
2y agoQNCXQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today
2y agoQNCXQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceBusiness WireQuince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today